Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

COMP360 psilocybin · COMP-360, CY-39

Small molecule · developed by COMPASS Pathways

Phase 2/3 Most advanced trial

CMPS Developer

1 Registered trials

What is COMP360 psilocybin?

COMP360 is a psilocybin formulation administered with monitoring and support. It is being studied in post-traumatic stress disorder (PTSD).

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: COMP-360, CY-39
Drug type: Small molecule
Therapy area: Psychiatry
Developer: COMPASS Pathways (CMPS, CMPX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII: 2RV7212BP0

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07570654	Phase 2/3	PTSD - Post Traumatic Stress Disorder	Recruiting	CMPS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

PTSDPTSD - Post Traumatic Stress DisorderPTSD Symptoms

More from COMPASS Pathways

CTX-10726 Phase 1 CTX-471 Phase 1/2 CTX-8371 Phase 1 Psilocybin Phase 3 Tovecimig Phase 2/3

Sources

ClinicalTrials.gov NCT07570654

Updated Oct 3, 2026. Something wrong or missing? Report it on the CMPS page.

Follow CMPS, the company behind COMP360 psilocybin

See CMPS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CMPS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z